Free tool
FAERS Monitor: Enbumyst
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219500 or its brand name (Enbumyst, Bumetanide). Reports on generic versions are filed under their own applications.
Reports
20,456
Serious
15,798
77% of reports
Hospitalization
9,658
Death reported
3,059
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,981
- acute kidney injury1,414
- fatigue1,340
- death1,290
- diarrhoea1,251
- nausea1,149
- dizziness1,004
- headache984
- pneumonia847
- hypotension760
- renal failure745
- fall735
- asthenia726
- chronic kidney disease726
- pain695
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 176 |
| 2005 | 224 |
| 2006 | 205 |
| 2007 | 195 |
| 2008 | 202 |
| 2009 | 209 |
| 2010 | 260 |
| 2011 | 357 |
| 2012 | 446 |
| 2013 | 465 |
| 2014 | 609 |
| 2015 | 931 |
| 2016 | 1,178 |
| 2017 | 1,236 |
| 2018 | 1,430 |
| 2019 | 1,547 |
| 2020 | 1,562 |
| 2021 | 1,172 |
| 2022 | 1,111 |
| 2023 | 1,478 |
| 2024 | 1,886 |
| 2025 | 2,037 |
| 2026 | 1,540 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,703 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 726 | 9.9 | 9.2 | 5,772 |
| acute kidney injurySignal | 1,414 | 9.6 | 9.1 | 10,835 |
| renal failureSignal | 745 | 5.8 | 5.4 | 2,953 |
| hypotensionSignal | 760 | 3.9 | 3.6 | 1,650 |
| dyspnoeaSignal | 1,981 | 3.6 | 3.5 | 3,820 |
| pneumoniaSignal | 847 | 2.7 | 2.5 | 912 |
| fallSignal | 735 | 2.3 | 2.1 | 530 |
| dizzinessSignal | 1,004 | 2.1 | 2.0 | 568 |
| diarrhoea | 1,251 | 2.0 | 1.9 | 638 |
| asthenia | 726 | 2.0 | 1.9 | 361 |
| fatigue | 1,340 | 1.8 | 1.7 | 465 |
| headache | 984 | 1.6 | 1.5 | 236 |
| death | 1,290 | 1.5 | 1.5 | 254 |
| nausea | 1,149 | 1.5 | 1.4 | 194 |
| pain | 695 | 1.2 | 1.1 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.